scispace - formally typeset
K

Kenan Zhang

Researcher at Capital Medical University

Publications -  44
Citations -  1447

Kenan Zhang is an academic researcher from Capital Medical University. The author has contributed to research in topics: Glioma & Medicine. The author has an hindex of 13, co-authored 31 publications receiving 497 citations.

Papers
More filters
Journal ArticleDOI

Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients.

TL;DR: Wang et al. as mentioned in this paper developed the Chinese Glioma Genome Atlas (CGGA), a userfriendly data portal for the storage and interactive exploration of cross-omics data, including nearly 2000 primary and recurrent glioma samples from Chinese cohort.
Posted ContentDOI

Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data for Chinese Glioma Patients

TL;DR: The Chinese Glioma Genome Atlas (CGGA) is developed, a user-friendly data portal for storage and interactive exploration of multi-dimensional functional genomic data that includes nearly 2,000 primary and recurrent glioma samples from Chinese cohorts and develops an analysis tool to allow users to browse mutational, mRNA/microRNA expression, and DNA methylation profiles and perform survival and correlation analyses of specificglioma subtypes.
Journal ArticleDOI

circRNA disease: a manually curated database of experimentally supported circRNA-disease associations.

TL;DR: The circRNA disease database provides a user friendly, open access web interface that allows users to browse, search, and upload the circRNA-disease association in the database, and may serve as an immeasurable resource for understanding the roles of circRNAs in diseases.
Journal ArticleDOI

m6A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas.

TL;DR: It is demonstrated that most of the thirteen main m6A RNA methylation regulators are differentially expressed among gliomas stratified by different clinicopathological features in 904gliomas, and derived a risk signature that is not only an independent prognostic marker but can also predict the clinicopathic features of glioma malignancy.
Journal ArticleDOI

YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma.

TL;DR: In this paper, the role and mechanism of the RNA N6,2′-O-dimethyladenosine (m6A) reader, YTH N6-methyladenosines RNA binding protein 2 (YTHDF2), in regulating the malignant progression of gliomas was investigated.